WHO Approves Essential Medicines for Multiple Sclerosis while Obesity Drugs are Excluded

By Danélia Botes

August 10, 2023

The World Health Organization (WHO) has made a significant move in global health by releasing new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc). These lists include new medicines for the treatment of multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions among others.

The aim? To increase access to innovative medicines that show clear clinical benefits, without stretching the health budgets of low- and middle-income countries.

With a record 85 applications considered, the updated lists now include a total of 502 medicines on the EML and 361 on the EMLc.

For the first time, medicines for the treatment of Multiple Sclerosis (MS), such as cladribine, glatiramer acetate, and rituximab have been included in the EML. These drugs can delay or slow the progression of MS, offering improved access to treatment for people living with this chronic condition. MS affects approximately 2.8 million people worldwide.
However, it’s important to note that obesity drugs including glucagon-like peptide-1 receptor agonists for weight loss, were not included in the updated EML. This decision is based on the EML’s criteria, which only includes medicines that have solid evidence for safety and efficacy.

Reference url

Recent Posts

South African National Health Insurance Bill

High Court on South African National Health Insurance Bill

📢Latest update on the NHI! 📢 Dive into our latest piece on the judicial review of the South African National Health Insurance Bill. Learn about the intriguing case and its implications on the healthcare industry. 🏛️💼💡 #HealthcarePolicy #LegalReview #NationalHealthInsuranceBill

Global Perspective on Orphan Medicines

A Global Perspective on Orphan Medicines and Rare Diseases

Discover the global perspective on orphan medicines and their role in treating rare diseases. Learn about the unique challenges and incentives in their development. 🌍💊 #OrphanMedicines #RareDiseases #HealthcareInnovation #RareDiseaseDay. Read more here


The Impact of Universal Health Coverage on Poverty Reduction in Low and Middle-Income Countries

📚 New research findings alert! 🚨 A recent study shows that increasing coverage of maternal, child and inpatient services is associated with reduced poverty in low and middle-income countries. 💡 This supports pro-poor approaches towards Universal Health Coverage. 🌍 Let’s work together to ensure #HealthForAll and #EndPoverty. Read more here 📖 #UHC #GlobalHealth #HealthEquity

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.